293 related articles for article (PubMed ID: 19060016)
1. Expression of GATA-6 transcription factor in pleural malignant mesothelioma and metastatic pulmonary adenocarcinoma.
Lindholm PM; Soini Y; Myllärniemi M; Knuutila S; Heikinheimo M; Kinnula VL; Salmenkivi K
J Clin Pathol; 2009 Apr; 62(4):339-44. PubMed ID: 19060016
[TBL] [Abstract][Full Text] [Related]
2. WT1 mutation in malignant mesothelioma and WT1 immunoreactivity in relation to p53 and growth factor receptor expression, cell-type transition, and prognosis.
Kumar-Singh S; Segers K; Rodeck U; Backhovens H; Bogers J; Weyler J; Van Broeckhoven C; Van Marck E
J Pathol; 1997 Jan; 181(1):67-74. PubMed ID: 9072005
[TBL] [Abstract][Full Text] [Related]
3. Osteopontin is linked to p65 and MMP-9 expression in pulmonary adenocarcinoma but not in malignant pleural mesothelioma.
Frey AB; Wali A; Pass H; Lonardo F
Histopathology; 2007 May; 50(6):720-6. PubMed ID: 17493236
[TBL] [Abstract][Full Text] [Related]
4. Novel marker D2-40, combined with calretinin, CEA, and TTF-1: an optimal set of immunodiagnostic markers for pleural mesothelioma.
Mimura T; Ito A; Sakuma T; Ohbayashi C; Yoshimura M; Tsubota N; Okita Y; Okada M
Cancer; 2007 Mar; 109(5):933-8. PubMed ID: 17279584
[TBL] [Abstract][Full Text] [Related]
5. Expression of inducible nitric oxide synthase in healthy pleura and in malignant mesothelioma.
Soini Y; Kahlos K; Puhakka A; Lakari E; Säily M; Pääkkö P; Kinnula V
Br J Cancer; 2000 Oct; 83(7):880-6. PubMed ID: 10970689
[TBL] [Abstract][Full Text] [Related]
6. Expression of cytokeratin 5/6 in epithelial neoplasms: an immunohistochemical study of 509 cases.
Chu PG; Weiss LM
Mod Pathol; 2002 Jan; 15(1):6-10. PubMed ID: 11796835
[TBL] [Abstract][Full Text] [Related]
7. Expression and prognostic significance of hypoxia-inducible factor 1alpha (HIF-1alpha) in malignant pleural mesothelioma (MPM).
Klabatsa A; Sheaff MT; Steele JP; Evans MT; Rudd RM; Fennell DA
Lung Cancer; 2006 Jan; 51(1):53-9. PubMed ID: 16169121
[TBL] [Abstract][Full Text] [Related]
8. Pleural mesothelioma in situ and its adenocarcinoma simulator.
Bono F
Int J Surg Pathol; 2010 Dec; 18(6):519-20. PubMed ID: 21081535
[No Abstract] [Full Text] [Related]
9. EGFR and PDGFR differentially promote growth in malignant epithelioid mesothelioma of short and long term survivors.
Kothmaier H; Quehenberger F; Halbwedl I; Morbini P; Demirag F; Zeren H; Comin CE; Murer B; Cagle PT; Attanoos R; Gibbs AR; Galateau-Salle F; Popper HH
Thorax; 2008 Apr; 63(4):345-51. PubMed ID: 18086752
[TBL] [Abstract][Full Text] [Related]
10. Clinical significance of the expression of tumor-associated antigen, RCAS1, and its soluble protein in pleural fluid in malignant mesothelioma.
Hiraki A; Aoe K; Murakami T; Nakamura Y; Yamazaki K; Sueoka N; Taguchi K; Kamei T; Maeda T; Takeyama H; Kishimoto T; Nishimura M; Sugi K
Oncol Rep; 2005 Aug; 14(2):357-62. PubMed ID: 16012715
[TBL] [Abstract][Full Text] [Related]
11. Manganese superoxide dismutase as a diagnostic marker for malignant pleural mesothelioma.
Kahlos K; Pääkkö P; Kurttila E; Soini Y; Kinnula VL
Br J Cancer; 2000 Mar; 82(5):1022-9. PubMed ID: 10737384
[TBL] [Abstract][Full Text] [Related]
12. The value of ThinPrep and cytospin preparation in pleural effusion cytological diagnosis of mesothelioma and adenocarcinoma.
Ylagan LR; Zhai J
Diagn Cytopathol; 2005 Mar; 32(3):137-44. PubMed ID: 15690333
[TBL] [Abstract][Full Text] [Related]
13. Clinicopathological analysis of lung cancer resembling malignant pleural mesothelioma.
Kobashi Y; Matsushima T; Irei T
Respirology; 2005 Nov; 10(5):660-5. PubMed ID: 16268922
[TBL] [Abstract][Full Text] [Related]
14. Is D2-40 a useful marker for distinguishing malignant mesothelioma from pulmonary adenocarcinoma and benign mesothelial proliferations?
Deniz H; Kibar Y; Güldür ME; Bakir K
Pathol Res Pract; 2009; 205(11):749-52. PubMed ID: 19573998
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of membranous staining of mesothelioma.
King JA; Tucker JA
Cell Vis; 1998; 5(1):24-7. PubMed ID: 9660721
[TBL] [Abstract][Full Text] [Related]
16. Neurotensin expression and outcome of malignant pleural mesothelioma.
Alifano M; Loi M; Camilleri-Broet S; Dupouy S; Régnard JF; Forgez P
Biochimie; 2010 Feb; 92(2):164-70. PubMed ID: 19932148
[TBL] [Abstract][Full Text] [Related]
17. Coalescent pleural malignant mesothelioma and adenocarcinoma of the lung, involving only minor asbestos exposure.
Tsuzuki T; Ninomiya H; Natori Y; Ishikawa Y
Pathol Int; 2008 Jul; 58(7):451-5. PubMed ID: 18577116
[TBL] [Abstract][Full Text] [Related]
18. E2F-1 overexpression correlates with decreased proliferation and better prognosis in adenocarcinomas of Barrett oesophagus.
Evangelou K; Kotsinas A; Mariolis-Sapsakos T; Giannopoulos A; Tsantoulis PK; Constantinides C; Troupis TG; Salmas M; Kyroudis A; Kittas C; Gorgoulis VG
J Clin Pathol; 2008 May; 61(5):601-5. PubMed ID: 17908803
[TBL] [Abstract][Full Text] [Related]
19. Estrogen receptor-beta affects the prognosis of human malignant mesothelioma.
Pinton G; Brunelli E; Murer B; Puntoni R; Puntoni M; Fennell DA; Gaudino G; Mutti L; Moro L
Cancer Res; 2009 Jun; 69(11):4598-604. PubMed ID: 19487281
[TBL] [Abstract][Full Text] [Related]
20. Prognostic role of osteopontin expression in malignant pleural mesothelioma.
Cappia S; Righi L; Mirabelli D; Ceppi P; Bacillo E; Ardissone F; Molinaro L; Scagliotti GV; Papotti M
Am J Clin Pathol; 2008 Jul; 130(1):58-64. PubMed ID: 18550471
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
